Breaking News Instant updates and real-time market news.

AKRX

Akorn

$6.74

0.02 (0.30%)

, TEVA

Teva

$23.78

0.09 (0.38%)

12:18
11/13/18
11/13
12:18
11/13/18
12:18

Court rules Allergan's patents on Restasis are invalid, Bloomberg reports

The U.S. Court of Appeals for the Federal Circuit in Washington has affirmed a trial court decision that said Allergan's (AGN) patents on its Restasis eye drug are invalid, a victory for Teva (TEVA), Mylan (MYL) and Akorn (AKRX), Bloomberg reports. Reference Link

AKRX

Akorn

$6.74

0.02 (0.30%)

TEVA

Teva

$23.78

0.09 (0.38%)

AGN

Allergan

$163.97

0.15 (0.09%)

MYL

Mylan

$36.19

0.25 (0.70%)

  • 13

    Nov

  • 13

    Nov

  • 15

    Nov

AKRX Akorn
$6.74

0.02 (0.30%)

10/04/18
CHLM
10/04/18
UPGRADE
Target $11
CHLM
Buy
Akorn upgraded to Buy from Hold at Craig-Hallum
10/04/18
10/04/18
UPGRADE
Target $11

Buy
Akorn upgraded to Buy after 'overreaction' to court rule at Craig-Hallum
As previously reported, Craig-Hallum analyst Matt Hewitt upgraded Akorn (AKRX) to Buy from Hold saying that while the ruling in favor of Fresenius (FMS) by the Deleware Court of Chancery was a major disappointment for investors, the 50%-plus drop in Akorn's stock price these past few days is unwarranted and values the company well below what it is worth on a standalone basis. The analyst also lowered his price target for Akorn's shares to $11 from $14.
10/17/18
PIPR
10/17/18
UPGRADE
Target $9
PIPR
Overweight
Akorn upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Akorn (AKRX) to Overweight and raised his price target for the shares to $9 from $5. After taking a closer look at the company's base generics business in the wake of the lower court decision that sided with Fresenius (FSNUY) in its efforts to terminate its merger with Akorn, Amsellem believes annual EBITDA of no worse than $125M-$135M starting in 2019 is realistic. The analyst says that based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. Assuming Akorn loses its appeal, management "strongly suggested" that it address its cost structure, Amsellem tells investors in a research note.
10/17/18
10/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Infosys (INFY) upgraded to Market Perform from Underperform at William Blair WITH analyst Maggie Nolan citing Q2 results. 2. American Airlines (AAL), Delta Air Lines (DAL), and United Continental (UAL) upgraded to Buy from Hold at Deutsche Bank. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. 4. Workday (WDAY) upgraded to Outperform from Market Perform at Bernstein with analyst Mark Moerdler saying he determined that even if the ERP market moves reasonably slowly to the Cloud, it is large enough and the fact there are only a few vendors with a competitive SaaS solution should allow Workday to continue to gain share. 5. Domino's Pizza (DPZ) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying the pullback in the stock price is overdone and expects accelerated cost savings and solid comps to yield higher earnings, raising his FY20 EPS view to $12.01 from $11.72. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$23.78

0.09 (0.38%)

11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.
11/06/18
WELS
11/06/18
UPGRADE
Target $40
WELS
Outperform
Wells upgrades Mylan to Outperform, sees more upside after today's rally
Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.
11/05/18
11/05/18
UPGRADE
Target $27

Overweight
Teva upgraded to Overweight on turnaround potential at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Teva to Overweight from Equal Weight, citing three main reasons. First, he expects strong cost cutting to drive earnings that top consensus forecasts. Second, he believes new products should deliver sales that top consensus forecasts. Third, he believes the market will assign Teva shares a higher multiple as the company executes and drives net debt /EBITDA down. Risinger, who noted that his adjusted EBITDA estimates for 2019-2020 are 6%-8% above consensus, raised his price target on Teva shares to $27 from $20.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Teva upgraded to Overweight from Equal Weight at Morgan Stanley
AGN Allergan
$163.97

0.15 (0.09%)

11/13/18
LEER
11/13/18
INITIATION
Target $220
LEER
Outperform
Allergan initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started Allergan with an Outperform and $220 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Allergan, Goodman notes that management has finally rebased numbers and growth expectations to credible levels and the balance sheet is becoming less of a focus. Further, he believes the underlying growth of the base business is underappreciated.
11/12/18
LEER
11/12/18
INITIATION
Target $220
LEER
Outperform
Allergan initiated with an Outperform at Leerink
Leerink Partners analyst Marc Goodman started Allergan with an Outperform rating and $220 price target.
11/01/18
MZHO
11/01/18
NO CHANGE
Target $213
MZHO
Buy
Allergan selloff on 'optimistic' 2019 estimates overdone, says Mizuho
Mizuho analyst Irina Koffler lowered her price target for Allergan shares to $213 from $220 but remains a buyer of the stock with a Buy rating. The analyst attributes the weakness in shares of Allergan to "overly optimistic" 2019 estimates. However, the selloff is overdone, Koffler tells investors in a research note.
10/31/18
FBCO
10/31/18
NO CHANGE
Target $202
FBCO
Outperform
Allergan price target lowered to $202 from $213 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Allergan to $202 from $213 following Q3 earnings. The analyst notes that Q3 quarterly performance and 2018 guidance raise was somewhat expected, but comments around the outlook of some important products and operating margins for 2019 highlight new challenges the company must overcome while waiting for the pipeline to deliver. He reiterates an Outperform rating on the shares.
MYL Mylan
$36.19

0.25 (0.70%)

11/06/18
COWN
11/06/18
NO CHANGE
Target $31
COWN
Market Perform
Mylan business model looks broken, says Cowen
Cowen analyst Ken Cacciatore said Mylan's Q3 results confirm his thesis that the current business model looks broken. He said at some point a new product cycle needs to materialize, but in Mylan's case it hasn't happened in a material enough way. Cacciatore recommends avoiding the shares and he reiterated his Market Perform rating and $31 price target on Mylan.
11/06/18
WELS
11/06/18
UPGRADE
WELS
Outperform
Mylan upgraded to Outperform from Market Perform at Wells Fargo
11/06/18
11/06/18
UPGRADE
Target $42

Buy
Mylan upgraded to Buy after 'encouraging' Q3 report at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Jason Gerberry upgraded Mylan to Buy from Neutral, stating that its Q3 report provided encouraging updates regarding several of its business segments. He believes concerns around its broader portfolio look overdone as industry-level generic pricing is showing signs of stabilizing while the company also provided encouraging new product updates. Gerberry added that he views the 20% stock pullback as an attractive opportunity, but trimmed his price target on Mylan shares to $42 from $44 to reflect rebasing of EpiPen and generic Copaxone.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$37.72

1.02 (2.78%)

20:51
12/12/18
12/12
20:51
12/12/18
20:51
Syndicate
Biohaven Pharmaceutical 3.3M share Secondary priced at $37.25 per share »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

FIVE

Five Below

$101.38

1.86 (1.87%)

20:48
12/12/18
12/12
20:48
12/12/18
20:48
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$4.21

-0.89 (-17.45%)

20:28
12/12/18
12/12
20:28
12/12/18
20:28
Syndicate
Marinus Pharmaceuticals 12M share Secondary priced at $3.75 per share »

Jefferies and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

UNM

Unum Group

$30.27

-0.04 (-0.13%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Hot Stocks
Unum Group sees FY19 adjusted EPS growth of 4%-7% »

Sees FY19 tax rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CIEN

Ciena

$32.14

0.535 (1.69%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TDC

Teradata

$38.02

0.65 (1.74%)

20:18
12/12/18
12/12
20:18
12/12/18
20:18
Hot Stocks
Teradata targets 2021 recurring revenue growth of 14% »

Also sees 2021 gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

  • 20

    Dec

HESM

Hess Midstream Partners

$19.43

0.38 (1.99%)

19:09
12/12/18
12/12
19:09
12/12/18
19:09
Hot Stocks
Hess Midstream Partners sees FY19 adjusted EBITDA $550M-$575M »

Sees FY19: net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOCA

Tocagen

$11.22

-1.63 (-12.68%)

19:05
12/12/18
12/12
19:05
12/12/18
19:05
Syndicate
Tocagen 3M share Secondary priced at $10.00 per share »

Citi and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALL

Allstate

$82.37

-0.12 (-0.15%)

19:03
12/12/18
12/12
19:03
12/12/18
19:03
Hot Stocks
Allstate announces estimated November catastrophe losses of $685M »

Allstate announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$76.04

-0.64 (-0.83%)

19:01
12/12/18
12/12
19:01
12/12/18
19:01
Hot Stocks
Exxon makes final investment decision to develop West Barracouta gas project »

ExxonMobil said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$111.83

1.09 (0.98%)

, JCS

Communications Systems

$2.42

0.2 (9.01%)

19:00
12/12/18
12/12
19:00
12/12/18
19:00
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

NDSN

Nordson

$111.83

1.09 (0.98%)

JCS

Communications Systems

$2.42

0.2 (9.01%)

BW

Babcock & Wilcox

$0.77

0.0569 (7.94%)

FIVE

Five Below

$101.38

1.86 (1.87%)

BABA

Alibaba

$151.49

-0.34 (-0.22%)

TLRD

Tailored Brands

$20.16

0.32 (1.61%)

LLNW

Limelight Networks

$3.20

0.025 (0.79%)

OXM

Oxford Industries

$74.88

0.895 (1.21%)

AGTC

Applied Genetic

$6.61

0.54 (8.90%)

VBIV

VBI Vaccines

$1.66

0.08 (5.06%)

HASI

Hannon Armstrong

$23.10

-0.16 (-0.69%)

BVN

Buenaventura

$15.25

0.22 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 04

    Mar

  • 12

    Mar

  • 13

    Dec

  • 13

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:58
12/12/18
12/12
18:58
12/12/18
18:58
Earnings
Oxford Industries cuts FY18 EPS view to $4.20-$4.35 from $4.45-$4.65 »

Cuts FY18 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:56
12/12/18
12/12
18:56
12/12/18
18:56
Earnings
Oxford Industries sees Q4 EPS 96c-$1.11 vs. 93c last year »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:55
12/12/18
12/12
18:55
12/12/18
18:55
Earnings
Oxford Industries reports Q3 adjusted EPS 14c vs. 17c last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NEXT

NextDecade

$4.74

0.04 (0.85%)

18:30
12/12/18
12/12
18:30
12/12/18
18:30
Hot Stocks
NextDecade's Rio Grande LNG project approved by TCEQ »

NextDecade Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.63

1.49 (1.69%)

18:15
12/12/18
12/12
18:15
12/12/18
18:15
Periodicals
United CEO seeks to boost flight network by 4%-6% next year, Reuters says »

United Airlines CEO Oscar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

AKAO

Achaogen

$1.80

0.06 (3.45%)

17:58
12/12/18
12/12
17:58
12/12/18
17:58
Hot Stocks
Breaking Hot Stocks news story on Achaogen »

Robert Duggan raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$34.11

0.29 (0.86%)

17:56
12/12/18
12/12
17:56
12/12/18
17:56
Hot Stocks
Fluor announces participation in $2.1B rail project in Chicago »

Fluor announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIVE

Five Below

$101.38

1.86 (1.87%)

17:55
12/12/18
12/12
17:55
12/12/18
17:55
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:49
12/12/18
12/12
17:49
12/12/18
17:49
Hot Stocks
SEC says former execs behind allegedly fraudulent ICO settle scam charges »

Two former executives…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$28.90

0.12 (0.42%)

17:37
12/12/18
12/12
17:37
12/12/18
17:37
Hot Stocks
CenterPoint Energy raises dividend 4% to 28.75c per share »

The company's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$27.47

0.51 (1.89%)

17:34
12/12/18
12/12
17:34
12/12/18
17:34
Syndicate
Breaking Syndicate news story on Upland Software »

Upland Software files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

GNTY

Guaranty Bancshares

$29.78

0.13 (0.44%)

17:32
12/12/18
12/12
17:32
12/12/18
17:32
Syndicate
Breaking Syndicate news story on Guaranty Bancshares »

Guaranty Bancshares files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.